Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors

Genetic interaction networks in cancer cells

(2019) Barbara Mair et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish

(2019) Evisa Gjini et al.   Disease Models & Mechanisms

Targeting epigenetics using synthetic lethality in precision medicine

(2018) Ee Sin Chen   CELLULAR AND MOLECULAR LIFE SCIENCES

Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

(2018) Narjust Duma et al.   Current Oncology Reports

TET2 in Normal and Malignant Hematopoiesis

(2017) Robert L. Bowman et al.   Cold Spring Harbor Perspectives in Medicine

PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment

(2016) Lu Zhao et al.   EXPERIMENTAL HEMATOLOGY

DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders

(2016) Hanae Sato et al.   Frontiers in Oncology

Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype

(2015) J.-S. Ahn et al.   HAEMATOLOGICA

PARP inhibitors: a treatment option for AML?

(2015) Lan Wang et al.   NATURE MEDICINE

Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors

(2015) Maria Teresa Esposito et al.   NATURE MEDICINE

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute loss of TET function results in aggressive myeloid cancer in mice

(2015) Jungeun An et al.   Nature Communications

Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype

(2015) J.-S. Ahn et al.   HAEMATOLOGICA

TET2as an epigenetic master regulator for normal and malignant hematopoiesis

(2014) Hideaki Nakajima et al.   CANCER SCIENCE

Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis

(2014) Wen-Jian Liu et al.   LEUKEMIA & LYMPHOMA

A Zebrafish Model of Myelodysplastic Syndrome Produced throughtet2Genomic Editing

(2014) Evisa Gjini et al.   MOLECULAR AND CELLULAR BIOLOGY

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage

(2014) Benu Brata Das et al.   NUCLEIC ACIDS RESEARCH

Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel

(2013) Rui Gao et al.   DNA REPAIR

Efficient Gene Targeting in Zebrafish Mediated by a Zebrafish-Codon-Optimized Cas9 and Evaluation of Off-Targeting Effect

(2013) Da Liu et al.   Journal of Genetics and Genomics

Efficient genome editing in zebrafish using a CRISPR-Cas system

(2013) Woong Y Hwang et al.   NATURE BIOTECHNOLOGY

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia

(2012) S Wakita et al.   LEUKEMIA

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

(2011) W.-C. Chou et al.   BLOOD

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets

(2011) D C Gilbert et al.   BRITISH JOURNAL OF CANCER

Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish

(2010) N. Bolli et al.   BLOOD

Hematopoietic Stem Cell Development Is Dependent on Blood Flow

(2009) Trista E. North et al.   CELL